Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment 5. Debunking Myths in the US Healthcare System
Top Ten Searches
aldosteronism contrast dialysis vitamin d bicarbonate arf amyloidosis hypocalcemia renal artery husYour Article Summary
Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma
Journal of Cancer Research & Clinical Oncology, 06/24/09
Schrader AJ et al. - In a study to assess whether different body mass index (BMI) levels at the time of surgery had an effect on long-term prognosis of renal cell carcinoma (RCC) pts, being overweight was identified as an independent prognostic marker of improved tumor-specific survival in pts with organ-confined RCC.
Methods- 771 pts, with complete information about their BMI, who had undergone renal surgery for RCC were evaluated.
- Mean follow-up was 5.48 yrs.
- Underweight, normal weight, pre-obesity, and obesity were diagnosed in 4 (0.5%), 239 (31%), 356 (46.2%), and 172 (22.3%) RCC pts, respectively.
- Overweight (BMI >25) was significantly associated with younger age and positive nodal status, but not with tumor stage, grade, visceral metastasis, gender, histological subtype, or tumor-related symptoms.
- Overweight pts had a significantly lower risk of cancer-related death; their median 5-yr tumor-specific survival rate was 80% vs 72% for pts with a BMI <25.
- Subgroup analysis revealed that the positive association between overweight and survival was even more pronounced in organ-confined RCC, but no correlation was observed in advanced disease.
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Pseudopheochromocytoma: An uncommon cause of malignant hypertension
Indian Journal of Nephrology, 10/16/09
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
A Randomized Controlled Study of Weekly and Biweekly Dosing of Epoetin Alfa in CKD Patients With Anemia
Clinical Journal of the American Society of Nephrology, 11/05/09
Article Search
Sponsor


See Latest Articles


